Page 225 - Haematologica Vol. 110 - January 2025

LETTER TO THE EDITOR
Authors
Lili Feng,1,2 Haohai Zhang,1 Changchuin Mao,3,4 Paola de Andrade Mello,1 Dina Stroopinsky,5 Eva Csizmadia,1 Jialin Zhou,6 David Avigan,5 Jinming Yu,6 Wenda Gao3,4# and Simon C. Robson1,7#
1Center for Inflammation Research, Department of Anesthesia, Critical Care & Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; 2Department of Hematology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, P. R. China; 3Antagen Institute for Biomedical Research, Canton, MA, USA; 4Antagen Pharmaceuticals, Inc. Canton, MA, USA; 5Department of Bone Marrow Transplantation, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; 6Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, P. R. China and 7Department of Medicine, Division of Gastroenterology/Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Correspondence:
W. GAO - wendagao01@gmail.com
S.C. ROBSON - srobson@bidmc.harvard.edu
https://doi.org/10.3324/haematol.2024.285547
Received: March 29, 2024. Accepted: August 6, 2024. Early view: August 15, 2024.
©2025 Ferrata Storti Foundation Published under a CC BY-NC license
Disclosures
WG is the founder and directs the Antagen Institute for Biomedical
References
1. Kuek V, Hughes AM, Kotecha RS, Cheung LC. Therapeutic targeting of the leukaemia microenvironment. Int J Mol Sci. 2021;22(13):6888.
2. Aroua N, Boet E, Ghisi M, et al. Extracellular ATP and CD39 activate cAMP-mediated mitochondrial stress response to promote cytarabine resistance in acute myeloid leukemia. Cancer Discov. 2020;10(10):1544-1565.
3. Allard B, Longhi MS, Robson SC, Stagg J. The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets. Immunol Rev. 2017;276(1):121-144.
4. Virgilio FD, Vultaggio-Poma V, Sarti AC. P2X receptors in cancer growth and progression. Biochem Pharmacol. 2021;187:114350.
5. Feng L, Cai Y, Zhu M, Xing L, Wang X. The yin and yang functions of extracellular ATP and adenosine in tumor immunity. Cancer Cell Int. 2020;20:110.
6. Feng L, Sun X, Csizmadia E, et al. Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine
Research. SCR is a scientific founder of Purinomia Biotech Inc and has provided consultancy services for eGenesis and SynLogic Inc; his interests are reviewed and managed by HMFP at Beth Israel Deaconess Medical Center in accordance with conflict-of-interest policies. The remaining authors declare that they have no competing financial interests.
Contributions
SCR, LF and WG conceptualized the experimental study and interpreted data. LF, HZ and WG developed the methodology. LF, HZ, CM, PM, DS, EC and JZ carried out the investigation. LF wrote the original draft of the manuscript. WG and SCR reviewed and edited the manuscript. LF and WG generated figures. SCR, DA, JY and LF acquired funding. SCR and WG provided resources. DA and SCR jointly supervised the study.
Funding
This research was supported by the National Institute of Health (R01 DK108894; R21 CA164970 to SR and R21 CA221702 to both SR and DA) and Department of Defense Award W81XWH-16-0464 (to SR), the National Natural Science Foundation of China (82030082, 82002719 and 82172676) and the Natural Science Foundation of Shandong (ZR2021YQ52 and ZR2023MH233), together with scholarship awards from the China Scholarship Council to LF.
Data-sharing statement
The data supporting the findings of this study are available within the article and the Online Supplementary Materials. Datasets and sequence information presented in this study can be accessed through the National Center for Biotechnology Information home page at https://www.ncbi.nlm.nih.gov under accession numbers SUB14589598. Other original data and full experimental protocols are immediately available to other investigators, with reasonable restrictions, from the corresponding authors. Additional data that support the findings of this study are also available on request from the corresponding authors, in agreement with the Data Management and Sharing (DMS) policy of the National Institutes of Health.
triphosphate. Neoplasia. 2011;13(3):206-216.
7. Longhi MS, Feng L, Robson SC. Targeting ectonucleotidases to
treat inflammation and halt cancer development in the gut.
Biochem Pharmacol. 2021;187:114417.
8. Sun X, Wu Y, Gao W, et al. CD39/ENTPD1 expression by
CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor
growth in mice. Gastroenterology. 2010;139(3):1030-1040.
9. Zhang H, Feng L, de Andrade Mello P, et al. Glycoengineered
anti-CD39 promotes anticancer responses by depleting suppressive cells and inhibiting angiogenesis in tumor models. J Clin Invest. 2022;132(13):e157431.
10. Miyake K, Karasuyama H. The role of trogocytosis in the modulation of immune cell functions. Cells. 2021;10(5):1255.
11. Kagermeier-Schenk B, Wehner D, Ozhan-Kizil G, et al. Waif1/5T4 inhibits Wnt/β-catenin signaling and activates noncanonical Wnt pathways by modifying LRP6 subcellular localization. Dev Cell. 2011;21(6):1129-1143.
Haematologica | 110 January 2025
217